2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow GLPG1690: new trials by email Literature Review of GLPG1690 trials Research Report on GLPG1690
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care GLPG1690, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Terminated | Lakefront Biotherapeutics NV | 525 | 2018-11-28 | 2022-07-29 |
| A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care GLPG1690, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Terminated | Lakefront Biotherapeutics NV | 781 | 2018-11-05 | 2022-07-29 |
Idiopathic Pulmonary Fibrosis (2)
Lakefront Biotherapeutics NV (2)
Germany (2) · Japan (2) · United States (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Czechia (1) · Denmark (1) · France (1) · Greece (1) · Hungary (1) · Israel (1)
PMID 31179008, PMID 37159034, PMID 38288082, PMID 34662125
2018 (2)